Patent Application
20220054617
This application contains a Sequence Listing electronically submitted via EFS-Web to the United States Patent and Trademark Office as an ASCII text file entitled “0110_000581WO01_SL.txt” having a size of 74,966 bytes and created on Dec. 4, 2019. The information contained in the Sequence Listing is incorporated by reference herein.
The mosquito-borne flavivirus Zika virus (ZIKV), first discovered in Uganda in 1947,17 was consigned to obscurity for nearly 70 years, with sporadic cases occurring in Africa and Asia. In March 2015, however, ZIKV was identified in association with an outbreak of exanthematous illness in Brazil;19, 20 and by December 2015, the virus had spread widely in Brazil, resulting in an estimated 1.3 million cases with a presumptive diagnosis of ZIKV infection.21 ZIKV is now known to be a cause of congenital neurologic birth defects, notably microcephaly22-28 and has also been associated with potentially fatal complications.29-31 The incidence of dengue virus (DENV) infections, a widespread mosquito-borne flaviviral disease, is much higher than the incidence of ZIKV infections, causing approximately 100 million symptomatic infections per year in more than 125 countries.32 The incidence of dengue increased from 1.2 million in 2008 to more than 3.2 million in 2015.33 The threat of a possible epidemic of dengue fever now exists in Europe, given that autochthonous transmission has been reported in France34 and in other European countries.35, 36 Dengue has been a long-standing problem in South Asia. India's first dengue fever epidemic was reported in 1964, spreading in a northward march from the southern peninsula to the foothills of the Himalayas. Extensive epidemics have followed, interspersed with endemic/hyper-endemic years,37, 38 and in 2015, New Delhi recorded its worst outbreak since 2006 with over 15,000 cases. Sri Lanka has also been particularly affected; Pro-Med Mail has reported more than 17,600 cases in the first two months of 2017, with 24 deaths.
The four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) exhibit essentially identical tropism (for example, monocytes, macrophages and dendritic cells),61,62 and elicit indistinguishable clinical manifestations. An individual infected with one of the four DENV serotypes usually develops long-lived, protective immunity against the primary strain (homotypic immunity); however, the individual can later be exposed to serotypes other than the one eliciting protective immunity. The low affinity and avidity characteristics of the antibodies elicited by the infection with the first strain can facilitate Antibody Dependent Enhancement (ADE) during subsequent DENV infections by enhancing the targeting of DENV-antibody complexes to Fcγ receptor (FcγR) bearing cells, and subsequent internalization of the virion.67-73
Yellow fever (YF) virus is also a mosquito-borne flavivirus, causing an acute infection with clinical manifestations ranging from mild non-specific illness to severe disease leading to multiple system organ failure, which is associated with mortality rates up to 50%. Several epidemics of YF have devastated populations in Africa and the Americas since the 17th century.39-42 An outbreak in the mid-1980s centered in Nigeria developed into a series of epidemics between 1986 and 1991, with 16,230 cases and 3633 deaths.43 On much of the African continent—with a population of 1.2 billion—YF is now considered endemic. An outbreak in Brazil is currently ongoing, with 1345 suspected cases (from December 2016 to Feb. 22, 2017), and 215 deaths;44 thousands of non-human primates have also succumbed to the disease, raising the specter of extinctions of endangered species.
This disclosure describes a subunit vaccine for a flavivirus, methods of making the vaccine, and methods of using the vaccine.
The term “dengue virus” refers to a group of four genetically and antigenically related viruses (DENV-1, DENV-2, DENV-3, and DENV-4).
The term “antibody-dependent enhancement” or “ADE” as used herein refers to phenomena characterized by non-neutralizing (or sub-optimally neutralizing) antibodies that facilitate virus entry into host cells, leading to increased infectivity in the cells. In some embodiments, ADE refers to a significant a detectable increase in viral infection in the presence of an antibody, relative to a preimmune sample or an unrelated antibody.
The term “subunit vaccine” refers to a vaccine that is capable of presenting an antigen from a microbe (for example, a viral particle) to the immune system without introducing the complete microbe.
As used herein “sequence identity” between two polypeptides is determined by comparing the amino acid sequence of one polypeptide to the sequence of a second polypeptide. When discussed herein, whether any particular polypeptide is at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to another polypeptide can be determined using methods and computer programs/software known in the art such as, but not limited to, the BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711). BESTFIT uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981), to find the best segment of homology between two sequences. When using BESTFIT or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference polypeptide sequence and that gaps in homology of up to 5% of the total number of amino acids in the reference sequence are allowed.
The words “preferred” and “preferably” refer to embodiments of the invention that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the invention.
The terms “comprises” and variations thereof do not have a limiting meaning where these terms appear in the description and claims.
Unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one.
Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (for example, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
For any method disclosed herein that includes discrete steps, the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously.
Reference throughout this specification to “one embodiment,” “an embodiment,” “certain embodiments,” or “some embodiments,” etc., means that a particular feature, configuration, composition, or characteristic described regarding the embodiment is included in at least one embodiment of the disclosure. Thus, the appearances of such phrases in various places throughout this specification are not necessarily referring to the same embodiment of the disclosure. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherently contain a range necessarily resulting from the standard deviation found in their respective testing measurements.
All headings are provided for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.
The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.
This disclosure describes a subunit vaccine for a flavivirus, methods of making the vaccine, and methods of using the vaccine. In some embodiments, the flavivirus is a mosquito-borne flavivirus. In some embodiments, the flavivirus includes at least one of Zika virus (ZIKV), dengue virus (DENV), Yellow Fever (YF) virus, and West Nile Virus (WNV). DENV can include any one of the DENV serotypes (for example, DENV-1, DENV-2, DENV-3, and DENV-4).
In preferred embodiments, the vaccine described herein is preferably a subunit vaccine—that is, a vaccine that includes a viral antigen that is capable of being presented to the immune system without introducing an entire viral particle.
The vaccines described herein include at least one antigen. Preferably, when the antigen is presented to the immune system, a response is elicited against at least one flavivirus. In some embodiments, the flavivirus is a mosquito-borne flavivirus. In some embodiments, the flavivirus includes at least one of Zika virus (ZIKV), dengue virus (DENV), Yellow Fever (YF) virus, and West Nile Virus (WNV). DENV can include any one of the DENV serotypes (for example, DENV-1, DENV-2, DENV-3, and DENV-4).
In some embodiments, the antigen may include a sequence set forth in Table 4 (SEQ ID NOs 1-6), a sequence set forth in Table 5A (SEQ ID NOs 7-12), or a sequence having at least 50%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to at least one of the sequences of Table 4 (SEQ ID NOs 1-6) or Table 5A (SEQ ID NOs 7-12).
In some embodiments, the vaccine includes more than one antigen including, for example, more than one flavivirus antigen. For example, the vaccine may include a mixture of DENV-1/-2/-3/-4 antigens. In some embodiments, a vaccine may include a mixture of DENV-1/-2/-3/-4 antigens, ZIKV antigen, and WNV antigen. In some embodiments, one or more of the antigens included in the vaccine has a sequence as shown in Table 4 or Table 5A. In some embodiments, one or more of the antigens included in the vaccine has at least 50%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to at least one of the sequences of Table 4 (SEQ ID NOs 1-6) or Table 5A (SEQ ID NOs 7-12).
In some embodiments, the vaccine preferably includes more than one antigen (including, for example, an antigen from ZIKV, WNV, and/or any one of the DENV serotypes) and elicits a response against at least one flavivirus, at least two flaviviruses, or at least three flaviviruses. In some embodiments, the vaccine does not elicit antibody-dependent enhancement. In some embodiments, the vaccine does not elicit immune interference.
For example, in some embodiments, the vaccine may include two of the sequences of Table 4 (SEQ ID NOs 1-6) and Table 5A (SEQ ID NOs 7-12), three of the sequences of Table 4 (SEQ ID NOs 1-6) and Table 5A (SEQ ID NOs 7-12), four of the sequences of Table 4 (SEQ ID NOs 1-6) and Table 5A (SEQ ID NOs 7-12), five of the sequences of Table 4 (SEQ ID NOs 1-6) and Table 5A (SEQ ID NOs 7-12), all of the sequences of Table 4 (SEQ ID NOs 1-6), or all of the sequences of Table 5A (SEQ ID NOs 7-12).
In some embodiments, the vaccine may further include a tag, and, in some embodiments, the antigen may be operably linked to the tag. A tag may include a maltose binding protein (MBP), a small ubiquitin-like modifier (SUMO) (Panavas et al. Methods Mol Biol. 2009; 497:303-17), a Glutathione S-transferase (GST), a Streptococcal G protein (SGp), etc., or combinations and/or portions thereof.
As used herein, the term “operably linked” refers to direct or indirect covalent linking. Thus, two domains that are operably linked may be directly covalently coupled to one another. Conversely, the two operably linked domains may be connected by mutual covalent linking to an intervening moiety (for example, and flanking sequence). Two domains may be considered operably linked if, for example, they are separated by the third domain, with or without one or more intervening flanking sequences.
For example, in some embodiments, the tag may include at least one of the sequences of Table 5B (SEQ ID NOs 13-14). In some embodiments, the antigen may include a sequence having at least 50%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to at least one of the sequences of Table 5B (SEQ ID NOs 13-14).
In some embodiments, the tag may be selected for its binding to albumin (human, non-human primate, pig, rabbit, rat, mouse). In some embodiments, the tag may be selected for its lack of binding to immunoglobulins. Without wishing to be bound by theory, it is believed that the binding to albumin facilitates delivery of the antigen to the lymph nodes while the abrogation of binding to immunoglobulins may obviate problems with affinity maturation of the resultant antibody response. For example, as described in Example 7, a portion of SGp may be used that binds to albumin but not to immunoglobulins.
In another aspect this disclosure describes methods of making the vaccine including, for example, making a vaccine including a tag and/or a protease cleavage site.
In some embodiments, the sequence encoding the antigen may be linked to a sequence (for example, a gene) encoding a tag such that the resulting antigen is operably linked to a tag. In some embodiments, the sequence encoding a tag may include a maltose binding protein (MBP) sequence, a small ubiquitin-like modifier (SUMO) sequence (Panavas et al. Methods Mol Biol. 2009; 497:303-17), a Glutathione S-transferase (GST) sequence, a Streptococcal G protein (SGp) sequence, etc., or combinations and/or portions thereof.
For example, in some embodiments, the tag may include a sequence that encodes a protein having at least one of the sequences of Table 5B (SEQ ID NOs 13-14). In some embodiments, the tag may include a sequence that encodes a protein having at least 50%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to at least one of the sequences of Table 5B (SEQ ID NOs 13-14).
In some embodiments, a protease cleavage site may be included between the sequence encoding the antigen and the sequence encoding the tag. Any suitable protease cleavage site may be used. In some embodiments, the protease cleavage site can include, for example, at least one of a TEV Protease cleavage site, an Enteropeptidase cleavage site, a thrombin cleavage site, a Factor Xa cleavage site, and a Rhinovirus 3C Protease cleavage site.
In some embodiments, the subunit vaccine described herein is preferably administered with an adjuvant. Any suitable adjuvant may be used. An adjuvant may include, for example, a suspensions of mineral (alum, aluminum hydroxide, aluminum phosphate) onto which antigen is adsorbed; an emulsion, including water-in-oil, and oil-in-water (and variants thereof, including double emulsions and reversible emulsions); a liposaccharides; a lipopolysaccharide; an immunostimulatory nucleic acid (such as a CpG oligonucleotide); a liposome; a Toll-like Receptor (TLR) agonist (for example, TLR2, TLR4, TLR7/8 and TLR9 agonists); and various combinations thereof.
In some embodiments, the adjuvant is preferably a TLR agonist.
In some embodiments, the adjuvant is preferably a covalent conjugate of an imidazoquinoline TLR7/TLR8 dual agonist [5-(3-(aminomethyl)benzyl)-3-pentylquinolin-2-amine]with hyaluronic acid (also referred to herein as EY-4-143) (
EY-4-143 is inert in vitro. It is inactive in TLR-7 and -8 primary assays, and is also silent in cytokine induction assays using either human whole blood or PBMCs; EY-4-143, however, is a potent adjuvant. A depot effect for EY-4-143 has been observed: at the site of injection as well as in the draining lymph node, there is a low-level, but sustained release of the TLR7/8 agonist. A comparison of equivalent doses of the free unconjugated imidazoquinoline with EY-4-143 in a reporter mouse model indicates that the systemic exposure of the EY-4-143 is very small relative to the unconjugated imidazoquinolines, signifying very low reactogenic potential and a high margin of safety. Without wishing to be bound by theory, the superior adjuvantic effects of EY-4-143 in combination with the vaccines disclosed herein are believed to be attributable, at least in part, to this depot effect.
The present disclosure provides a pharmaceutical composition that includes a vaccine as described herein, and a pharmaceutically acceptable carrier. The vaccine is formulated in a pharmaceutical composition and then, in accordance with the method of the invention, administered to a vertebrate, particularly mammal, such as a human patient, primate, research animal, or domesticated animal, in a variety of forms adapted to the chosen route of administration. The formulations include those suitable for oral, rectal, vaginal, topical, nasal, ophthalmic, or parenteral (including subcutaneous, intramuscular, intraperitoneal, and intravenous) administration.
The pharmaceutically acceptable carrier can include, for example, an excipient, a diluent, a solvent, an accessory ingredient, a stabilizer, a protein carrier, or a biological compound. Non-limiting examples of a protein carrier includes keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, or the like. Non-limiting examples of a biological compound which can serve as a carrier include a glycosaminoglycan, a proteoglycan, and albumin. The carrier can be a synthetic compound, such as dimethyl sulfoxide or a synthetic polymer, such as a polyalkyleneglycol. Ovalbumin, human serum albumin, other proteins, polyethylene glycol, or the like can be employed as the carrier. In some embodiments, the pharmaceutically acceptable carrier includes at least one compound that is not naturally occurring or a product of nature.
The formulations can be conveniently presented in unit dosage form and can be prepared by any of the methods well-known in the art of pharmacy. In some embodiments, a method includes the step of bringing the vaccine into association with a pharmaceutical carrier. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulations.
Formulations of the present disclosure suitable for oral administration can be presented as discrete units such as tablets, troches, capsules, lozenges, wafers, or cachets, each containing a predetermined amount of the vaccine as a powder or granules, as liposomes, or as a solution or suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, an emulsion, or a draught. The tablets, troches, pills, capsules, and the like can also contain one or more of the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, fructose, lactose, or aspartame; and a natural or artificial flavoring agent. When the unit dosage form is a capsule, it can further contain a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials can be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules can be coated with gelatin, wax, shellac, sugar, and the like. A syrup or elixir can contain one or more of a sweetening agent, a preservative such as methyl- or propylparaben, an agent to retard crystallization of the sugar, an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol, a dye, and flavoring agent. The material used in preparing any unit dosage form is substantially nontoxic in the amounts employed. The vaccine can be incorporated into preparations and devices in formulations that may or may not be designed for sustained release.
Formulations suitable for parenteral administration conveniently include a sterile aqueous preparation of the vaccine, or dispersions of sterile powders of the vaccine, which are preferably isotonic with the blood of the recipient. Parenteral administration a vaccine (e.g., through an I. V. drip) is one form of administration. Isotonic agents that can be included in the liquid preparation include sugars, buffers, and sodium chloride. Solutions of the vaccine can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions of the vaccine can be prepared in water, ethanol, a polyol (such as glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, glycerol esters, and mixtures thereof. The ultimate dosage form is sterile, fluid, and stable under the conditions of manufacture and storage. In some embodiments, the necessary fluidity can be achieved, for example, by using liposomes, by employing the appropriate particle size in the case of dispersions, or by using surfactants. Sterilization of a liquid preparation can be achieved by any convenient method that preserves the bioactivity of the vaccine, including, for example, by filter sterilization. Preferred methods for preparing powders include vacuum drying and freeze drying of the sterile injectable solutions. Subsequent microbial contamination can be prevented using various antimicrobial agents, for example, antibacterial, antiviral and antifungal agents including parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Absorption of the vaccine over a prolonged period may be achieved by including agents for delaying, for example, aluminum monostearate and gelatin.
Nasal spray formulations include purified aqueous solutions of the vaccine with preservative agents and isotonic agents. Such formulations may preferably be adjusted to a pH and isotonic state compatible with the nasal mucous membranes. Formulations for rectal or vaginal administration can be presented as a suppository with a suitable carrier such as cocoa butter, or hydrogenated fats or hydrogenated fatty carboxylic acids. Ophthalmic formulations may prepared by a similar method to the nasal spray, except that the pH and isotonic factors are preferably adjusted to match that of the eye. Topical formulations include the vaccine dissolved or suspended in one or more media such as mineral oil, petroleum, polyhydroxy alcohols, or other bases used for topical pharmaceutical formulations. Topical formulations may be provided in the form of a bandage, wherein the formulation is incorporated into a gauze or other structure and brought into contact with the skin.
A subunit vaccine, as described herein, can be administered to a subject alone or in a pharmaceutical composition that includes the vaccine and a pharmaceutically acceptable carrier. The vaccine may be administered to a vertebrate, more preferably a mammal, such as a human patient, a companion animal, or a domesticated animal, in an amount effective to produce the desired effect. The vaccine may be administered in a variety of routes, including orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery by catheter or stent, subcutaneously, intraadiposally, intraarticularly, intrathecally, or in a slow release dosage form.
The formulations may be administered as a single dose or in multiple doses. Useful dosages of the vaccine may be determined by comparing their in vitro activity and the in vivo activity in animal models. Methods for extrapolation of effective dosages in rabbits, mice, primates, and other animals, to humans are known in the art.
Dosage levels of the vaccine in the pharmaceutical compositions of this disclosure can be varied so as to obtain an amount of the vaccine which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level will depend upon a variety of factors including the route of administration, the time of administration, the adjuvant being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the vaccine, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well known in the medical arts.
Dosages and dosing regimens that are suitable for other vaccines may likewise be suitable for therapeutic or prophylactic administration of the vaccines described herein.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the vaccine and/or pharmaceutical composition required.
1. A subunit vaccine for a flavivirus, the vaccine comprising an antigen, the antigen comprising a sequence having at least 80% sequence identity to one of SEQ ID NO:1 to SEQ ID NO:12.
2. The subunit vaccine of Embodiment 1, wherein the antigen comprises a sequence having at least 90% sequence identity to one of SEQ ID NO:1 to SEQ ID NO:12.
3. The subunit vaccine of either of Embodiments 1 or 2, wherein the antigen comprises a sequence comprising one of SEQ ID NO:1 to SEQ ID NO:12.
4. A subunit vaccine for a flavivirus, the vaccine comprising an antigen consisting of a sequence having at least 80% sequence identity to one of SEQ ID NO:1 to SEQ ID NO:12.
5. The subunit vaccine of Embodiment 4, the antigen consisting of a sequence having at least 90% sequence identity to one of SEQ ID NO:1 to SEQ ID NO:12.
6. The subunit vaccine of Embodiments 4 or 5, the antigen consisting of a sequence selected from the group consisting of one of SEQ ID NO:1 to SEQ ID NO:12.
7. The subunit vaccine of any one of Embodiments 1 to 6, wherein the flavivirus comprises at least one of Zika virus (ZIKV), dengue virus (DENV), Yellow Fever (YF) virus, and West Nile Virus (WNV).
8. The subunit vaccine of Embodiment 7, wherein DENV comprises at least one of DENV-1, DENV-2, DENV-3, and DENV-4.
9. The subunit vaccine of any one of Embodiments 1 to 6, wherein the vaccine further comprises a tag, wherein the tag is fused to the antigen.
10. The subunit vaccine of Embodiment 9, wherein the tag comprises a maltose binding protein (MBP), a small ubiquitin-like modifier (SUMO), a Glutathione S-transferase (GST), a Streptococcal G protein (SGp), or combinations and/or portions thereof.
11. The subunit vaccine of Embodiment 9 or 10, wherein the tag comprises SEQ ID NO:13.
12. The subunit vaccine of any of Embodiments 9 to 11, wherein the tag comprises SEQ ID NO:14.
13. A pharmaceutical composition comprising:
the subunit vaccine of any one of Embodiments 1 to 12, and
a pharmaceutically acceptable carrier.
14. The composition of Embodiment 13, the composition further comprising an adjuvant.
15. The composition of Embodiment 14, the adjuvant comprising hyaluronic acid.
16. The composition of Embodiments 14 or 15, the adjuvant comprising a TLR agonist.
17. The composition of Embodiment 16, the TLR agonist comprising at least one of a TLR 7 and a TLR 8 agonist.
18. The composition of Embodiment 16, the TLR agonist comprising [5-(3-(aminomethyl)benzyl)-3-pentylquinolin-2-amine].
19. The composition of any one of Embodiments 13 to 18, the adjuvant comprising a covalent conjugate of hyaluronic acid and a TLR agonist.
20. The composition of any one of Embodiments 13 to 19, the adjuvant comprising
21. A method of making the subunit vaccine of any one of Embodiments 1 to 12.
22. The method of Embodiment 21, wherein the method comprises expressing a construct comprising a sequence encoding the antigen, wherein the resulting antigen is operably linked to a tag.
23. The method of Embodiment 21 or 22, wherein the method comprises expressing a construct comprising the antigen and a sequence encoding a tag, wherein the construct further comprises a protease cleavage site between the sequence encoding the antigen and the sequence encoding the tag.
24. The method of Embodiment 23, wherein the protease cleavage site comprises a TEV protease cleavage site.
25. The method of any of Embodiments 21 to 24, wherein the tag comprises a maltose binding protein (MBP), a small ubiquitin-like modifier (SUMO), a Glutathione S-transferase (GST), a Streptococcal G protein (SGp), or combinations and/or portions thereof.
26. The method of any of Embodiments 21 to 25, wherein the tag comprises SEQ ID NO:13.
27. The method of any of Embodiments 21 to 26, wherein the tag comprises SEQ ID NO:14.
28. The method of any one of Embodiments 21 to 27, the method further comprising cleaving the tag from the antigen.
29. The method of Embodiment 28, wherein the tag is cleaved from the antigen by TEV protease.
30. A method comprising administering the subunit vaccine of any one of Embodiments 1 to 12.
31. A method comprising administering the composition of any one of Embodiments 13 to 20.
32. The method of Embodiment 30 or 31, wherein the subunit vaccine does not elicit antibody-dependent enhancement.
33. The method of Embodiment 30 or 31, wherein the subunit vaccine does not elicit immune interference.
The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.
The vectors used were modified from the ligation independent cloning (LIC) vector pTBSG described in Qin et al. (BMC Biotechnol. 2008, 8:51). The maltose binding protein (MBP) gene was amplified by PCR using the sense primer 5′-GGACTAGTAAAATCGAAGAAGGTAAACTG-3′ (SEQ ID NO: 16) and anti-sense primer 5′-CGGGGTACCAGTCTG CGCGTCTTTCAG-3′ (SEQ ID NO: 17). The PCR products were digested with restriction enzymes SpeI and KpnI, and then ligated into the pTBSG vector digested with the same enzymes.
Target genes were codon optimized, synthesized (Integrated Gene Technologies, Coralville, Iowa), and amplified by PCR using a pair of primers in which the sense primer began with the sequence 5′-TACTTCCAATCCAATGCA-3′ (SEQ ID NO: 18) followed by the target gene and the anti-sense primer began with the sequence 5′-TTATCCACTTCCAATG-3′ (SEQ ID NO: 19) followed by the complement of a stop codon and the C-terminus of the target gene. The volume of a typical reaction mixture was 50 μL, and the product was purified using a YM-30 spin column (Microcon, Inc.) and recovered in 50 μL of buffer including 50 mM Tris (pH 8.0) and 1 mM EDTA. The vector (with or without fusion partners) was digested with Ssp1 for two hours and applied to DNA agarose electrophoresis. The band corresponding to the cleaved vector was carefully sliced and recovered from the gel using the QIAGEL extraction Kit (Qiagen, Hilden, Germany) and then treated with T4 DNA polymerase (Novagen, LIC quality, EMD Millipore, Billerica, Mass.) in the presence of dGTP. The insert was treated with dCTP and T4 DNA polymerase at room temperature for 30 minutes then heated at 75° C. for 20 minutes to stop the reaction. Annealing was carried out simply by mixing 1 μL of the digested vector, 2 μL of the insert, and 1 μL of EDTA (25 mM, pH 8.0) and incubated at room temperature for 5 minutes. The annealed plasmid was transformed into DH5a competent cells. Positive clones were screened by PCR and then sequenced. Cloned genes were transformed into the expression host, BL21(DE3)-pRARE (KanPro, Inc., Lawrence, Kans.).
E. coli cells harboring the expression vector were grown on LB agar plates containing 100 μg/mL ampicillin and 34 μg/mL chloramphenicol. A single clone was picked and inoculated into 3 mL LB media for overnight growth. 100 μL of the overnight culture was then inoculated into 10 mL LB media, and the expression was induced with the addition of 0.4 mM IPTG when OD600 reached 0.6. The culture was grown for an additional 4 hours at 37° C., or overnight at 17° C. Cells were harvested by centrifugation at 4500 g for 15 min at 4° C., resuspended in 1 mL lysis buffer (10 mM Tris-HCl, pH 8.0, 0.5 M NaCl) and lysed by sonication (Sonic Dismembrator, Model 100, Fischer Scientific, Inc.) three times (15 sec each). The lysate was fractionated by centrifugation for 20 min at 10,000 g. The supernatant normally contained soluble proteins and fragmented membranes, while the pellet consisted of insoluble proteins (inclusion body fraction). The supernatant was subjected to ultracentrifugation at 100,000 g for 45 min at 8° C. to separate the membrane and soluble protein fractions. The soluble, insoluble and membrane fractions were adjusted to the same volume with lysis buffer, and then 20 μL of each was mixed with 20 μL sample buffer (2×) and 10 μL was loaded on 12% MOPS SDS-PAGE gels followed by either Coomassie staining. Control experiments were performed under the same experimental conditions without IPTG induction.
Small-scale purification of each of the target subunit immunogen proteins was studied using a 10 mL culture described as above. Each construct was expressed in 10 mL cultures as described above. The soluble fraction was collected in 50 mM Tris-HCl, pH 8, 500 mM NaCl at 4° C. After centrifugation at 195,000 rpm for 30 min at 4° C., the supernatant was mixed with 100 μL Ni2+-NTA resin (Sigma) which was pre-equilibrated with the wash buffer (50 mM Tris-HCl, pH 8, 500 mM NaCl). After incubation at 4° C. overnight with gentle shaking, the resin was extensively washed with the wash buffer and then eluted with the elution buffer (50 mM Tris-HCl, pH 8, 500 mM NaCl, and 250 mM imidazole). Insoluble protein was dissolved in the buffer dissolving buffer (50 mM Tris-HCl, pH 8, 500 mM NaCl, 6 M urea), incubate with NiNTA resin, washed and eluted in 50 mM Tris-HCl, pH 8, 500 mM NaCl, 250 mM imidazole.
The adjuvant used herein is a covalent conjugate of an imidazoquinoline TLR7/TLR8 dual agonist [5-(3-(aminomethyl)benzyl)-3-pentylquinolin-2-amine] with hyaluronic acid (also referred to herein as EY-4-143) (
Pre-immune test-bleeds are first obtained from adult New Zealand White rabbits via venipuncture of the marginal vein of the ear on Day 1. The rabbits are immunized intramuscularly in the flank region with (a) 10 μg of antigen in 0.2 mL saline (n=4 for non-adjuvanted, antigen+saline control cohort), or (b) 10 μg of antigen plus 100 μg of adjuvant in 0.2 mL saline (n=4 for antigen+adjuvant test cohorts). An aqueous formulation for all adjuvants and antigens is ensured. Animals are immunized on Days 1, 15, and 28. A final test-bleed is performed via the marginal vein of the ear on Day 38. Sera may be banked at −80° C. for further analysis.
A homogeneous assay was developed to quantify neutralization of ZIKV, and the consequent inhibition of cell death. The assay was adapted and standardized to 384-well plate formats, and the assay allows either near-real-time kinetic acquisition for six 384-well plates per experiment, or endpoint acquisition at the zenith of viral-induced cell death (3 days for ZIKV) for more than fifty 384-well plates.
Briefly, Vero cells were plated at a density of 105 cells/mL in a 384-well plate (Plate 1). Separately, paired pre-immune/immune rabbit sera were serially diluted in 384-well plates in DMEM cell culture media containing propidium iodide (PI) at a concentration of 20 μg/mL (Plate 2). A stock of Zika virus was diluted so as to achieve a final multiplicity of infection (MOI) of 1, and added to the diluted pre-immune/immune sera wells. The plate was pre-incubated for 3 hours at 37° C. Following pre-incubation, samples from each well (Plate 1) containing serially diluted sera and virus were transferred onto the Vero cells (Plate 2). Cell death (indicated by PI staining of nuclei) was monitored in real-time using an IncuCyte imaging instrument (Essen BioScience, Inc., Ann Arbor, Mich.).
DENV-infected Vero cells also exhibit cytopathic effect leading to cell death, with the kinetics of CPE and cell death being not only time-dependent, but also a function of the multiplicity of infection and the strain of DENV. Analyses of the cell killing curves indicated that a significantly longer acquisition (up to 6 days) was necessary to capture DENV-induced CPE.
The pan-flavivirus 4G2 monoclonal antibody recognizes flavivirus group specific antigens (ZIKV, DENV, WNV, Japanese encephalitis virus (JEV), and YF) by binding to the fusion loop at the terminus of domain II of the E glycoprotein.130-132 Intracellular E-glycoprotein content is a function of internalization (immediate post-infection), as well as replication.
An indirect immunofluorescence method was developed to quantify in vitro neutralization titers in antisera in Vero cells infected with ZIKV/DENV/YF17D. Vero cells are plated at a density of 105 cells/mL in 384-well plates and infected at an MOI of 5 in the presence of serially diluted preimmune/immune rabbit sera. After an appropriate incubation period (for example, 3 days for ZIKV and YF17D, 4.5 days for DENV), cells are washed, permeabilized and fixed with 4% paraformaldehyde. A 1:500 dilution of 4G2, followed by anti-mouse IgG-AlexaFluor488 conjugate at a dilution of 1:200 (and PI for nuclear counterstain) is used for direct interrogation and quantitation of infected cells in a high-throughput manner (>20 plates/experiment).
Quantitation of ZIKV Copy Number Using qRT-PCR.
Total RNA from 96 samples are extracted concurrently using an Aurum Total RNA 96 Kit (Bio-Rad, Hercules, Calif.). cDNA synthesis of the ZIKV strand is carried out with the reverse primer (5′-CTGTTCCACACCA CAAGCAT-3′ (SEQ ID NO: 20)) and an initial hybridization at 65° C.
Standard Superscript II Reverse Transcriptase/RNase H protocols. qPCR is performed on a CFX-96 Real Time System (Bio-Rad, Hercules, Calif.) with the following primers for ZIKV NS5: Forward primer: 5′-AGGCTGAGGAAGTGCTAGAG-3′ (SEQ ID NO: 21); Reverse primer: 5′-TGAGGGCATGTGCAAACCTA-3′ (SEQ ID NO: 22). The resultant amplicon length is 164 nucleotides with a melting temperature of 82.5° C. Detection limit: 5 copies/mL.
Neutralizing antibodies were assessed using GFP-expressing recombinant viral particles (ZIKV, WNV, DENV-1, DENV-2, DENV-3, DENV-4); cellular infection was assayed using longitudinal intravital epifluorescence microscopy and automated image analysis on an INCUCYTE instrument (Essen BioScience, Inc., Ann Arbor, Mich.).
Because neutralizing antibodies against DENV and ZIKV may be directed to its surface-expressed E (ENV) glycoprotein, and given the high degree of sequence similarity between DENV and ZIKV, the crystal structure of DENV ENV protein (post-fusion conformation, soluble fragment, PDB coordinates: 1OK8) was used as a point of departure. Domain III (involved in receptor binding, and a major site for neutralizing antibodies) is discontinuous with Domain II (membrane fusion domain) and Domain I (
In silico modeling of a re-engineered DENV-E having and amphipathic membrane fusion Domain II excised and the resultant discontinuous sequences ligated sequences with appropriate spacer peptides yielded a sequence which, on template-based protein structure modeling using RaptorX,101-103 predicted a tertiary structure that faithfully reproduced the overall P-barrel fold topology of Domains I and III (
The ZIKV antigen of Table 1 was fused to MBP and was expressed as described in the MATERIALS section. The antigen was tested using the Standardized Rabbit Model of Immunogenicity. Very high titers of anti-ZIKV antibodies were elicited in rabbits, but no neutralization was observed in vitro.
Because no neutralization was observed using the antigen of Example 1, several modifications of the ZIKV sequence used in Example 1 were tested. After several iterations, sera from rabbits immunized with 10 μg/dose of a maltose binding protein (MBP)-ZIKV E-glycoprotein fusion construct having the sequence shown in Table 2 (which is much shorter than the fusion construct of Example 1) was obtained, and ZIKV-neutralizing activity was observed in the sera (
Because of concerns of the Original Antigenic Sin59, and Antibody Dependent Enhancement (ADE) documented in flaviviral infections67-73, whether antisera raised against MBP-ZIKV would exhibit ADE (or heterologous protection) against DENV-1, DENV-2, DENV-3, DENV-4 or YF17F was examined. Neither ADE, nor heterologous protection was observed.
A comparison of the relative mases of the His-tag/MBP fragment (376 residues, 41,437.9 Daltons) versus the ZIKV fragment (108 residues, 11,717.4 Daltons) indicated that the MBP fragment, while allowing correct folding of the protein and greatly enhancing yields of soluble protein, was quite large and could be immunodominant. The Tobacco Etch Virus (TEV) protease136, 137 cut site that was engineered in the protein (see
To isolate the ZIKV fragment from the fusion protein, a large-scale batch of the fusion protein was expressed, purified, and cleaved using TEV protease (also having a His-tag). The cleavage reaction was performed at 4° C. overnight. Before re-loading on the Ni2+-NTA resin (approximate 4 mg of cleaved fusion protein/mL resin) to remove the MBP fragment and the TEV (both have an N-terminal His-tag), the sample was dialyzed against the dialysis buffer (PBS plus 88 mM mannitol) for 4 hours to remove imidazole. Re-loading was performed at 4° C. and flow-through fractions containing the ZIKV fragment was collected and characterized in detail using a range of techniques not only to assess purity, but also to verify disulfide formation, monodisperisty, and conformational homogeneity as described below. 15N-labeled ZIKV fragment was also isolated for 15N/1H heteronuclear single quantum coherence spectroscopy138 (HSQC) NMR experiments.
Size exclusion chromatography showed a monomeric species eluting at a volume corresponding to 12 kDa, and LC-MS on an accurate mass QTOF instrument showed the expected mass of 11,717.95 Daltons, indicating that the two cysteines were oxidized (intramolecular disulfide). A melting temperature of 54.2° C. in thermal shift assays with SYPRO Orange139, 140, indicated a stable, well-folded structure, which was confirmed by 15N-1H heteronuclear single quantum coherence (HSQC) NMR experiments.
This fragment, in conjunction with EY-4-143 as an adjuvant, was evaluated using the standardized rabbit immunogenicity modified as follows: an antigen concentration of 50 μg/dose was used.
Immune-1 sera (obtained a week following the 1st boost), Immune-2 sera (obtained after the 2nd boost), as well as pre-immune sera were examined for anti-ZIKV IgG in standard ELISAs. In vitro neutralization of ZIKV was quantified using both the CPE/cell-death assay and 4G2 immunostaining which interrogates intracellular ZIKV E-glycoprotein content. When adjuvanted with EY-4-143, the ZIKV fragment at 50 mg/dose consistently elicited high neutralizing titers in all animals (n=4), even after a single boost. All six strains of ZIKV tested (Table 3) were neutralized. Representative data showing one of six plates from the CPE/cell death assay and 4G2 immunostain assay, obtained with ZIKV NR50221 (H/PAN/2015/CDC-259364), are shown in
This Example describes the immunogenicity, protective efficacy, and cross reactivity (in vitro) of DENV-1, DENV-2, DENV-3, DENV-4, and WNV antigens developed using the principles of antigen design described above for ZIKV.
Homology mapping of the ZIKV sequence to DENV-1, DENV-2, DENV-3, DENV-4 and WNV E-glycoprotein sequences yielded target sequences (see Table 4). An alignment of these sequences is provided in
Rabbits (n=4/cohort) were immunized with 10 μg DENV-1, DENV-2, DENV-3, DENV-4, or WNV antigens, as shown in Table 4, each adjuvanted with EY-4-143 (100 μg), as described in the Standardized Rabbit Model of Immunogenicity, to determine whether the antigens successfully induce neutralizing antibodies to the cognate strain (that is, homotypic protection in vitro).
All animals with the exception of the cohort immunized with DENV-3 showed in vitro neutralization. (
Additional rabbits will be immunized with 50 μg DENV-3 antigen, adjuvanted with EY-4-143, as described in the Standardized Rabbit Model of Immunogenicity. The increased dose of the antigen is expected to successfully induce neutralizing antibodies to the cognate strain.
A high degree of sequence similarity is observed even in the approximately 12 kDa C-terminal domain between ZIKV, the DENV strains, and WNV (
To examine the consequences of such cross-reactivity, noting that it could range from ADE to cross-protection (or no effect at all), the effect of sera from rabbits immunized with each antigen on viral replication of the other antigens was examined.
Sera from rabbits immunized with DENV-1, DENV-2, DENV-3, DENV-4 antigens exhibited sporadic low level inhibition of ZIKV replication (
This Example shows the Interaction of EY-4-143 with ZIKV, DENV-1, DENV-2, DENV-3 and DENV-4 antigens.
The calculated isoelectric point (pI) values for the ZIKV, DENV-1, DENV-2, DENV-3 and WNV antigens ranged between 6.2 and 6.4 and, consequently, significant Coloumbic interactions between the highly polyanionic hyaluronic acid backbone of EY-4-143 and the subunit immunogens were not expected.
However, during size exclusion chromatographic (SEC) characterization of the tetravalent DENV-1/DENV-2/DENV-3/DENV-4 construct, a dramatic shift in the elution profiles of the antigens before and after formulation with the adjuvant EY-4-143 was observed. The tetravalent antigen mixture in the absence of EY-4-143 behaved as expected, with the elution volume of the mixture (79.6 min) corresponding to mass of 12 kDa, indicating that there was no significant aggregation (or intermolecular interactions) between the four subunit antigens. Upon addition of EY-4-143, the antigens largely eluted in the void volume (43.8 min), suggesting that the antigens were complexed with EY-4-143, and in dynamic equilibrium favoring the complexed state (43.8 min peak) over the free, uncomplexed form (79.6 min). Additional evidence for strong interactions between the antigen and adjuvant was obtained in 15N/1H HSQC experiments, wherein the addition of EY-4-143 to 15N-labeled ZIKV antigen was found to specifically result in chemical shift perturbations of a few residues (
In preliminary immunogenicity screens with the ZIKV antigen, several candidate adjuvants were examined and only EY-4-143 was found to consistently elicit neutralizing antibodies after the first boost.
This Example describes the immunogenicity, protective efficacy, and cross reactivity (in vitro) of MBP2-DENV-1, MBP2-DENV-2, MBP2-DENV-3, MBP2-DENV-4, MBP2-WNV, and MBP2-ZIKV antigens.
Rabbits (n=4/cohort) were immunized with 10 μg per dose MBP2-DENV-1, MBP2-DENV-2, MBP2-DENV-3, MBP2-DENV-4, MBP2-WNV, or MBP2-ZIKV antigens, as shown in Table 6, or with 10 μg each per dose of MBP2-DENV-1, MBP2-DENV-2, MBP2-DENV-3, and MBP2-DENV-4 (“Tetravalent MBP2-DENV-(1-4)”), or with 10 μg each per dose of MBP2-DENV-1, MBP2-DENV-2, MBP2-DENV-3, MBP2-DENV-4, MBP2-WNV, and MBP2-ZIKV (“Hexavalent MBP2-ZIKV/WNV/DENV-(1-4)”), each adjuvanted with EY-4-143 (100 μg/dose), as described in the Standardized Rabbit Model of Immunogenicity, to determine whether the antigens successfully induce neutralizing antibodies. Neutralizing antibodies were assessed using GFP-expressing recombinant viral particles.
Results are shown in
MHHHHHH
STS
KIEEGKLVIWINGDKGYNGLAEV
EIAETQHGTIVVRVQYEGDGSPCKIPFEIMDLE
KRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDS
YIIIGVEPGQLKLSWFKK
MHHHHHH
STS
KIEEGKLVIWINGDKGYNGLAEV
EIAETQHGTIVVRVQYEGDGSPCKIPFEIMDLE
KRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDS
YIIIGVEPGQLKLSWFKK
MHHHHHH
STS
KIEEGKLVIWINGDKGYNGLAEV
VSETQHGTILIKVEYKGEDAPCKIPFSTEDGQG
KAHNGRLITANPVVTKKEEPVNIEAEPPFGESN
IVIGIGDNALKINWYKK
MHHHHHH
STS
KIEEGKLVIWINGDKGYNGLAEV
TPADTGHGTVVLELQYTGTDGPCKVPISSVASL
NDLTPVGRLVTVNPFVSVATANSKVLIELEPPF
GDSYIVVGRGEQQINHHWHKS
MHHHHHH
STS
KIEEGKLVIWINGDKGYNGLAEV
TPADTGHGTVVLELQYTGTDGPCKVPISSVASL
NDLTPVGRLVTVNPFVSVATANSKVLIELEPPF
GDSYIVVGRGEQQINHHWHKS
MHHHHHH
STS
KIEEGKLVIWINGDKGYNGLAEV
VPAETLHGTVTVEVQYAGTDGPCKIPVQMAVDM
QTLTPVGRLITANPVITESTENSKMMLELDPPF
GDSYIVIGVGDKKITHHWHRS
This Example describes the immunogenicity, protective efficacy, and cross reactivity (in vitro) of SGp(L)-DENV-1, SGp(L)-DENV-2, SGp(L)-DENV-3, SGp(L)-DENV-4, SGp(L)-WNV, and SGp(L)-ZIKV antigens.
Each antigen includes a portion of the Strepocococcal G protein (SGP) at the N-terminus. The SGP portion was selected for its good binding to albumin (human, non-human primate, pig, rabbit, rat, mouse), but not to immunoglobulins. Without wishing to be bound by theory, it is believed that the binding to albumin facilitates delivery of the antigen to the lymph nodes while the abrogation of binding to immunoglobulins obviates problems with affinity maturation of the resultant antibody response. (See, for example, Nilvebrant et al. Computational and Structural Biotech. J. 2013, 6(7):e201303009; Lejon et al., J. Biol. Chem. 2004, 279(41):42924-42928; Jonsson et al. Protein Engineering, Design and Selection 2008, 21(8):515-527.)
Rabbits (n=4/cohort) were immunized with 10 μg each antigen per dose as described in the Standardized Rabbit Model of Immunogenicity modified as shown in Table 8. Antigens are shown in Table 7; each dose was adjuvanted with EY-4-143 (100 μg/dose).
A rise in antibody titers, as measured by ELISA was comparable in cohorts A, B, and C (statistically insignificant differences; results are shown in
Neutralizing antibodies were assessed using GFP-expressing recombinant viral particles. Results are shown in
MHHHHHH
STS
LAEAKVLANRELDKYGVSDYYKNL
TGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIP
ISTQDEKGVTQNGRLITANPIVTDKEKPVNIETE
PPFGESYIVIGAGEKALKLSWFK
MHHHHHH
STS
LAEAKVLANRELDKYGVSDYYKNL
CTGKFKVVKEIAETQHGTIVVRVQYEGDGSPCKI
PFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEA
EPPFGDSYIIIGVEPGQLKLSWFKK
MHHHHHH
STS
LAEAKVLANRELDKYGVSDYYKNL
TNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP
FSTEDGQGKAHNGRLITANPVVTKKEEPVNIEAE
PPFGESNIVIGIGDNALKINWYKK
MHHHHHH
STS
LAEAKVLANRELDKYGVSDYYKNL
SGKFSIDKEMAETQHGTTVVKVKYEGTGAPCKVP
IEIRDVNKEKVVGRIISSTPFAENTNSVTNIELE
PPFGDSYIVIGVGDSALTLHWFR
MHHHHHH
STS
LAEAKVLANRELDKYGVSDYYKNL
CSKAFKFAGTPADTGHGTVVLELQYTGTDGPCKV
PISSVASLNDLTPVGRLVTVNPFVSVATANSKVL
IELEPPFGDSYIVVGRGEQQINHHWHKS
MHHHHHH
STS
LAEAKVLANRELDKYGVSDYYKNL
CTAAFTFTKVPAETLHGTVTVEVQYAGTDGPCKI
PVQMAVDMQTLTPVGRLITANPVITESTENSKMM
LELDPPFGDSYIVIGVGDKKITHHWHRS
The complete disclosure of all patents, patent applications, and publications, and electronically available material (including, for instance, nucleotide sequence submissions in, for example, GenBank and RefSeq, and amino acid sequence submissions in, for example, SwissProt, PIR, PRF, PDB, and translations from annotated coding regions in GenBank and RefSeq) cited herein are incorporated by reference. In the event that any inconsistency exists between the disclosure of the present application and the disclosure(s) of any document incorporated herein by reference, the disclosure of the present application shall govern. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.
This application claims the benefit of U.S. Provisional Application No. 62/778,347, filed Dec. 12, 2018, the disclosure of which is incorporated by reference herein in its entirety.
This invention was made with government support under 272201400056C awarded by the National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/065886 | 12/12/2019 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62778347 | Dec 2018 | US |
